Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights
Sunesis Pharmaceuticals (Nasdaq: SNSS) has announced a conference call on November 16, 2020, at 4:30 PM ET to discuss its Q3 financial results and corporate updates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sunesis Pharmaceuticals (Nasdaq: SNSS) has announced a conference call on November 16, 2020, at 4:30 PM ET to discuss its Q3 financial results and corporate updates.
The call can be accessed via phone or through a live audio webcast, which will also be available for replay on the company's website for two weeks.
The company focuses on developing targeted inhibitors for cancer treatment, including its first-in-class PDK1 inhibitor, SNS-510, which is currently in IND-enabling studies.
Details
News Market Reaction – SNSS
The recorded move for SNSS in the trading session of this news was +1.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2020.
The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (international) and entering passcode 1776248.
To access the live audio webcast, or the subsequent archived recording, visit the “Investors and Media – Calendar of Events” section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company’s website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib has completed a Phase 1b trial in patients with advanced B cell malignancies.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 | Par Hyare Sunesis Pharmaceuticals Inc. 650-266-3784 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.